Trial Profile
A Phase I Study to Determine the MTD and to Evaluate Pharmacokinetic, Safety/Tolerability, and Efficacy Profiles of IOP Injection for MRI Contrast Agent in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Iron oxide-PEG (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Megapro Biomedical Company
- 09 Jan 2017 Status changed from recruiting to completed.
- 27 Apr 2016 New trial record